AVBP
ArriVent BioPharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−4.64%
vs ±16.3% implied · ×0.29
shaded = implied · ▲▼ = realized
No thesis.
Fund move
Fund move
ArriVent BioPharma, Inc.
14.93
−1.02 · −6.41%
post 14.72 −1.39%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Suvretta Capital ManagementSuvretta | $156.9M | 9.59% | +2.60% | |
| 2 | Infinitum Asset ManagementInfinitum | $154.2M | 9.43% | +6.98% | |
| 3 | Hillhouse Capital AdvisorsHillhouse Capital | $136.5M | 8.35% | 0.00% | |
| 4 | BlackRockBlackRockindex-like | $112.9M | 6.91% | +28.46% | |
| 5 | Orbimed AdvisorsOrbimed | $105.2M | 6.43% | 0.00% | |
| 6 | FMRFMR | $96.5M | 5.90% | −7.86% | |
| 7 | Octagon Capital AdvisorsOctagon Capital | $68.5M | 4.19% | 0.00% | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $61.7M | 3.77% | +16.09% | |
| 9 | Sofinnova InvestmentsSofinnova | $58.9M | 3.60% | 0.00% | |
| 10 | State StreetState Streetindex-like | $58.8M | 3.60% | +19.11% | |
| 11 | Vivo CapitalVivo Capital | $58.4M | 3.57% | +89.87% | |
| 12 | NovoNovo | $52.1M | 3.19% | −22.77% | |
| 13 | General Catalyst Group ManagementGeneral Catalyst | $51.9M | 3.18% | 0.00% | |
| 14 | Logos Global ManagementLogos Global | $34.7M | 2.12% | +185.71% | |
| 15 | Geode Capital ManagementGeodeindex-like | $33.8M | 2.07% | +21.03% | |
| 16 | D. E. ShawD. E. Shaw | $30.3M | 1.85% | +136.45% | |
| 17 | Goldman Sachs GroupGoldman Sachs | $29.7M | 1.81% | +0.03% | |
| 18 | SC China HoldingSC China | $23.0M | 1.41% | 0.00% | |
| 19 | Point72 Asset ManagementPoint72 | $19.7M | 1.20% | −24.24% | |
| 20 | Susquehanna International GroupSusquehanna International | $19.6M | 1.20% | +196.27% | |
| 21 | Millennium ManagementMillennium | $15.2M | 0.93% | +2.99% | |
| 22 | UBS GroupUBS | $15.2M | 0.93% | −9.80% | |
| 23 | Balyasny Asset ManagementBalyasny | $13.7M | 0.84% | −7.23% | |
| 24 | Ameriprise FinancialAmeriprise Financial | $13.3M | 0.81% | +111.96% | |
| 25 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $11.6M | 0.71% | +32.09% |
158 managers report $1.6B of ArriVent BioPharma on form 13F for the quarter ended Jun 30 '26. 18 of them hold 80% of it; Suvretta is largest at 9.59%.
Expected move
No implied move.
No implied move.
No implied move.